Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in advanced NSCLC with COPD
NCT05578222Phase 2Unknown
- Sponsor
- Tianjin Chest Hospital
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Tianjin Chest Hospital. Primary endpoint: Progression-Free Survival at 30 months. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05578222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05578222.